Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries

Pain Clinical Trial

Official title:

A Randomised, Multicentre, Two-arm, Parallel Group, Double-blind, Placebo-controlled, Comparative Efficacy and Safety Clinical Study of Ibuprofen in Patients With Pain Related to Uncomplicated Ankle Injuries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01562717
• Other study ID #: 0028022
• Secondary ID: 2011-004497-28
• Status: Completed
• Phase: Phase 3
• First received: March 22, 2012
• Last updated: May 7, 2013
• Start date: February 2012
• Est. completion date: October 2012

Study information

• Verified date: October 2012
• Source: Orion Corporation, Orion Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Finnish Medicines AgencyLithuania: State Medicine Control Agency - Ministry of HealthPoland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to evaluate the efficacy and safety of Ibuprofen in patients with ankle injuries.

Description:

The objective of the study is to evaluate the efficacy and safety of Ibuprofen versus placebo in patients for the treatment of pain related to uncomplicated ankle injuries.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: October 2012
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Written informed consent obtained.

2. Male and female patients, age in the range of 18-45 years (inclusive).

3. Patients with pain related to uncomplicated ankle injuries (in case of doubt whether it is complicated an X-ray should be taken).

4. Pain related to ankle injuries is scored as moderate or severe by the patient and the injury is less than 24 hours old.

5. Patients with normal or clinically non-significant findings as determined by baseline history, physical examination and vital signs (blood pressure, heart rate and axillary temperature).

6. Comprehension of the nature and purpose of the study and compliance with the protocol requirements.

7. Negative urine pregnancy test (for females only).

Exclusion Criteria:

1. Known hypersensitivity to aspirin or any non-steroidal anti-inflammatory drugs (NSAID).

2. Known history of asthma.

3. Known history of gastric or peptic ulcer or bleeding.

4. Known history of malignancy or other serious diseases.

5. Known history of skin allergy.

6. Known history of cardiac, renal or hepatic insufficiency.

7. Presence of bruises or rash on the skin of ankle.

8. Presence of skin lesions like eczema or psoriasis.

9. Arthritis in the same joint.

10. Alcohol use during the study period or within 48 hours before the study enrolment.

11. Patients judged unable to use the VAS for pain reliably

12. Locally applied NSAID to the painful region/area of study or oral use of NSAID or other analgesics 48 hours before the study enrolment.

13. Other pain killers than rescue medication to be taken during the study.

14. Recurrent sprain at the same joint during the last 6 months.

15. Anticoagulant therapy.

16. Physiotherapy during study period.

17. Open wounds, infected skin or fracture.

18. Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the patient.

19. Pregnant or lactating females.

20. Participation in a drug or device study within 90 days before the study enrolment.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ankle Injuries
• Pain

Intervention

Drug:
• Ibuprofen
3 times a day
• Placebo
3 times a day

Locations

Country	Name	City	State
Finland	Terveystalo Lahti	Lahti

Sponsors (1)

Lead Sponsor	Collaborator
Orion Corporation, Orion Pharma

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy: VAS	VAS pain score change over time from baseline to day 7	Day 7	No
Secondary	Efficacy: VAS	Percentage VAS pain score change from baseline separately to day 3 and 7	Day 3 and Day 7	No